01:40 , Dec 30, 2016 |  BC Week In Review  |  Company News

Clinical Genomics sales and marketing update

Clinical Genomics launched its Colvera blood-based test in the U.S. to monitor the recurrence of colorectal cancer. Colvera is a PCR-based test that measures two epigenetically modified genes -- hyper-methylated cytosolic branched chain amino-acid transaminase...
00:58 , Mar 24, 2016 |  BC Extra  |  Financial News

Diagnostics play Clinical Genomics raises $15M

Clinical Genomics Pty. Ltd. (North Ryde, Australia) closed a $15 million series A round led by Australian venture firm OneVentures. This year, Clinical Genomics plans to launch its Gemini test in the U.S. for post-surgical...
08:00 , Feb 1, 2016 |  BC Week In Review  |  Clinical News

2-Gene Colorectal Cancer Recurrence Test: Clinical trial data

An analysis of 120 patients with known colorectal recurrence status following resection of a primary tumor showed that Clinical Genomics’ 2-Gene Colorectal Cancer Recurrence Test had an overall sensitivity of 63% and specificity of 86%...
07:00 , Aug 1, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Brain cancer Cytosolic branched chain amino-acid transaminase 1 (BCAT1); isocitrate dehydrogenase 1 (IDH1) Patient tissue and mouse studies suggest inhibiting BCAT1...